Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 6% - Here's What Happened

Key Points

• Ascentage Pharma shares rose 6% to $17.92, although trading volume was exceptionally light at about 302 shares versus an average of 6,879.
• Analysts remain bullish, with a consensus “Buy” rating and an average price target of $46.43; recent targets from B. Riley and BTIG were $45 and $48, respectively.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.65 per share on $22.24 million in revenue, while institutional investors including HSBC, UBS, and Citadel recently established or increased positions.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price rose 6% during trading on Friday . The company traded as high as $17.92 and last traded at $17.92. Approximately 302 shares were traded during trading, a decline of 96% from the average session volume of 6,879 shares. The stock had previously closed at $16.90.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a "buy" rating and a $45.00 price target for the company. Raymond James Financial restated a "buy" rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, BTIG Research reissued a "buy" rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The firm has a fifty day simple moving average of $18.21 and a two-hundred day simple moving average of $20.99.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million during the quarter. As a group, research analysts expect that Ascentage Pharma Group International - Unsponsored ADR will post -2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company's stock worth $716,000 after purchasing an additional 10,988 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the third quarter worth approximately $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source